tag tumour-microenvironment 
Pharma Times
JUNE 18, 2025
Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T cells within the tumour microenvironment, with the goal of amplifying anti-tumour T-cell activity while minimising systemic toxicities.
European Pharmaceutical Review
AUGUST 24, 2022
Early dose-limiting toxicities have prohibited the expansion of ADCs into larger and more complex tumour indications, dampening the initial hopes of a new “magic bullet” in the fight against cancer. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.
Expert insights. Personalized for you.
89 
Let's personalize your content